Bicycle Therapeutics (BCYC) PT Lowered to $42 at Jefferies

Jefferies analyst Biren Amin lowered the price target on Bicycle Therapeutics (NASDAQ: BCYC) to $42.00 (from $53.00) while maintaining a Buy rating.

The analyst comments "For the FY24 updates, BCYC highlighted Zele+pembo Ph1 data in 1L UC (65%/25% ORR/CR), and Ph2/3 Duravelo-2 dose selection data remains on track for 2H25. Co also highlighted zele data in NECTIN4 gene-amplified cancers w/ several Ph1/2 trials to start in '25. Multiple updates of radionuclide conjugates are expected from mid to 2H'25, and Co aims to start first clinical trial in '26. BCYC ended 4Q with $879.5M cash to provide a financial runway into 2H27."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Jane Street Took $15 Billion Hit In July Tied To Situational Awareness - Reuters
• Aurora Spine settles patent dispute, secures $600K insider loan